120 related articles for article (PubMed ID: 31349399)
1. Bimatoprost loaded nanovesicular long-acting sub-conjunctival in-situ gelling implant: In vitro and in vivo evaluation.
Yadav M; Guzman-Aranguez A; Perez de Lara MJ; Singh M; Singh J; Kaur IP
Mater Sci Eng C Mater Biol Appl; 2019 Oct; 103():109730. PubMed ID: 31349399
[TBL] [Abstract][Full Text] [Related]
2. Safety data on in situ gelling bimatoprost loaded nanovesicular formulations.
Yadav M; Guzman-Aranguez A; Perez de Lara MJ; Singh M; Singh J; Kaur IP
Data Brief; 2019 Aug; 25():104361. PubMed ID: 31485469
[TBL] [Abstract][Full Text] [Related]
3. Bimatoprost-loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment: in vitro and in vivo evaluation.
Franca JR; Foureaux G; Fuscaldi LL; Ribeiro TG; Rodrigues LB; Bravo R; Castilho RO; Yoshida MI; Cardoso VN; Fernandes SO; Cronemberger S; Ferreira AJ; Faraco AA
PLoS One; 2014; 9(4):e95461. PubMed ID: 24788066
[TBL] [Abstract][Full Text] [Related]
4. Ophthalmic Bimatoprost-Loaded Niosomal In Situ Gel: Preparation, Optimization, and In Vivo Pharmacodynamics Study.
Aldawsari MF; Moglad EH; Alotaibi HF; Alkahtani HM; Khafagy ES
Polymers (Basel); 2023 Nov; 15(21):. PubMed ID: 37960016
[TBL] [Abstract][Full Text] [Related]
5. Multiple drug delivery from the drug-implants-laden silicone contact lens: Addressing the issue of burst drug release.
Desai AR; Maulvi FA; Desai DM; Shukla MR; Ranch KM; Vyas BA; Shah SA; Sandeman S; Shah DO
Mater Sci Eng C Mater Biol Appl; 2020 Jul; 112():110885. PubMed ID: 32409042
[TBL] [Abstract][Full Text] [Related]
6. Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results From a Phase I/II Clinical Trial.
Lewis RA; Christie WC; Day DG; Craven ER; Walters T; Bejanian M; Lee SS; Goodkin ML; Zhang J; Whitcup SM; Robinson MR;
Am J Ophthalmol; 2017 Mar; 175():137-147. PubMed ID: 28012819
[TBL] [Abstract][Full Text] [Related]
7. Intracameral sustained release bimatoprost implants (Durysta).
Sirinek PE; Lin MM
Semin Ophthalmol; 2022 Apr; 37(3):385-390. PubMed ID: 34586961
[TBL] [Abstract][Full Text] [Related]
8. Safety assessment of subconjunctivally implanted devices containing latanoprost in Dutch-belted rabbits.
Jessen BA; Shiue MH; Kaur H; Miller P; Leedle R; Guo H; Evans M
J Ocul Pharmacol Ther; 2013; 29(6):574-85. PubMed ID: 23489175
[TBL] [Abstract][Full Text] [Related]
9. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
Easthope SE; Perry CM
Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
[TBL] [Abstract][Full Text] [Related]
10. Nanoemulsion-based electrolyte triggered in situ gel for ocular delivery of acetazolamide.
Morsi N; Ibrahim M; Refai H; El Sorogy H
Eur J Pharm Sci; 2017 Jun; 104():302-314. PubMed ID: 28433750
[TBL] [Abstract][Full Text] [Related]
11. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension.
Coleman AL; Lerner F; Bernstein P; Whitcup SM
Ophthalmology; 2003 Dec; 110(12):2362-8. PubMed ID: 14644719
[TBL] [Abstract][Full Text] [Related]
12. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.
Lopes JF; Hubatsch DA; Amaris P
BMC Ophthalmol; 2015 Nov; 15():166. PubMed ID: 26563363
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4.
Williams RD; Cohen JS; Gross RL; Liu CC; Safyan E; Batoosingh AL;
Br J Ophthalmol; 2008 Oct; 92(10):1387-92. PubMed ID: 18621791
[TBL] [Abstract][Full Text] [Related]
14. Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial.
DuBiner HB; Hubatsch DA
BMC Ophthalmol; 2014 Nov; 14():151. PubMed ID: 25432143
[TBL] [Abstract][Full Text] [Related]
15. A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension.
Natt NK; Gupta A; Singh G; Singh T
Indian J Ophthalmol; 2014 Dec; 62(12):1136-40. PubMed ID: 25579357
[TBL] [Abstract][Full Text] [Related]
16. Bimatoprost: mechanism of ocular surface hyperemia associated with topical therapy.
Chen J; Dinh T; Woodward DF; Holland M; Yuan YD; Lin TH; Wheeler LA
Cardiovasc Drug Rev; 2005; 23(3):231-46. PubMed ID: 16252016
[TBL] [Abstract][Full Text] [Related]
17. Natural Bioadhesive Biodegradable Nanoparticle-Based Topical Ophthalmic Formulations for Management of Glaucoma.
Ibrahim MM; Abd-Elgawad AH; Soliman OA; Jablonski MM
Transl Vis Sci Technol; 2015 Jun; 4(3):12. PubMed ID: 26175958
[TBL] [Abstract][Full Text] [Related]
18. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure.
Sherwood M; Brandt J;
Surv Ophthalmol; 2001 May; 45 Suppl 4():S361-8. PubMed ID: 11434939
[TBL] [Abstract][Full Text] [Related]
19. [Clinical tolerance of antiglaucoma eyedrops with and without a preservative. Results of an unpublished survey in Europe].
Levrat F; Pisella PJ; Baudouin C
J Fr Ophtalmol; 1999 Mar; 22(2):186-91. PubMed ID: 10327349
[TBL] [Abstract][Full Text] [Related]
20. Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase II Randomized Controlled Study.
Brandt JD; Sall K; DuBiner H; Benza R; Alster Y; Walker G; Semba CP;
Ophthalmology; 2016 Aug; 123(8):1685-1694. PubMed ID: 27157843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
